All notifications at a glance

Quote from C. Frick, CEO of Geratherm Medical AG: "We are proud and delighted to be supporting Marlene, an up-and-coming talent in the German biathlon team, in the World Cup, while at the same time…

Geratherm Medical AG is therefore taking another successful step in the reorientation of its portfolio.

Geratherm Medical AG starts 2025 with strong momentum: solid revenue growth, operating turnaround, and a robust financial position underline the company’s positive performance.

Geratherm has published its annual report for fiscal year 2024. Revenue declined by 33% to €14.0 million, primarily due to significant drops in Healthcare Diagnostics (-47%) and Incubator Systems…

Due to the ongoing difficult market situation, short-time working at the Geratal site for clinical thermometer production has been extended until 31 December 2025. 

This also affects our subsidiary…

Following Geratherm Medical AG's 20% stake in BIOThermare, a young company that produces environmentally friendly cold/warm compresses with a patented algae gel filling, another update was published…

The sale of apoplex medical technologies GmbH to a German-American consortium was successfully concluded as agreed and the pro rata purchase price was paid in full.

On October 30, 2024, the price target was updated following the announcement of the extension of short-time work at the Geratal site. ResearchHub continues to issue a Buy recommendation for the…

Another step in the realignment of Geratherm Medical AG has been taken. Geratherm Medical AG acquires 20% of the shares in BIOThermare GmbH, Obermichelbach.

BIOThermare GmbH is a leading manufacturer…

Due to the ongoing difficult market situation, short-time working at the Geratal site for clinical thermometer production will be extended until March 31, 2025.

The other divisions of the Geratherm…